AtriCure (NASDAQ:ATRC) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of AtriCure shares on August 20, according to a September 10 disclosure. The transaction was made through a Bank of America trust account.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analyst revenue estimates. The stock opened at $54.54, near its 12-month high of $55.72, while the company guided to fiscal 2026 EPS of $0.24–$0.32.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $52.00. However, company insiders have sold 65,036 shares worth approximately $2.76 million over the past 90 days.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on August 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 8/28/2026.
• Purchased $15,001 - $50,000 in shares of Quanta Services NYSE: PWR on 8/27/2026.
• Purchased $15,001 - $50,000 in shares of Eaton NYSE: ETN on 8/27/2026.
• Sold $15,001 - $50,000 in shares of NIKE NYSE: NKE on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Walmart NASDAQ: WMT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 8/26/2026.
• Sold $15,001 - $50,000 in shares of Lamar Advertising NASDAQ: LAMR on 8/25/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/25/2026.

AtriCure Stock Performance

ATRC stock opened at $54.54 on Friday. The firm has a market cap of $2.77 billion, a PE ratio of 259.73 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The business has a 50 day moving average of $42.41 and a 200-day moving average of $33.55. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $55.72.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In other news, insider Justin Noznesky sold 6,182 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company's stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Karen Prange sold 3,564 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company's stock, valued at $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 65,036 shares of company stock valued at $2,758,687. 4.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATRC. Tidal Investments LLC lifted its position in shares of AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company's stock worth $534,000 after acquiring an additional 6,034 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in AtriCure during the 2nd quarter worth about $1,002,000. Engineers Gate Manager LP boosted its stake in AtriCure by 12.3% in the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company's stock worth $1,348,000 after purchasing an additional 5,283 shares during the period. Integrated Wealth Concepts LLC bought a new position in AtriCure in the 2nd quarter worth about $46,000. Finally, Allworth Financial LP grew its holdings in AtriCure by 372.8% during the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company's stock valued at $43,000 after buying an additional 1,204 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Citigroup reissued a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. Zacks Research cut shares of AtriCure from a "strong-buy" rating to a "hold" rating in a report on Monday, August 24th. UBS Group dropped their price objective on AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. BTIG Research increased their price objective on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday, August 24th. Finally, Needham & Company LLC raised their target price on AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $52.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AtriCure Company Profile

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.